The study's focal point was the efficacy of ginkgo diterpene lactone meglumine (GDLM), an active component of ginkgo biloba, in aiding cognitive recuperation after a stroke. Conducted across 100 centers in China, this multicenter trial involved 3,163 stroke survivors. These individuals, grappling with mild to moderate ischemic stroke, commenced treatment within 48 hours of their stroke incident. They were randomized to receive either 25 mg of intravenous GDLM or a placebo daily for two weeks. Cognitive function was meticulously assessed at the outset, after 14 days, and again at 90 days using the Montreal Cognitive Assessment scale (MoCA).